Monoclonal Antibody Vaccines

Monoclonal antibodies (mAb or moAb) are antibodies made from the same immunocytes, which are clones of a single ancestral cell. Monoclonal antibodies bind to the same epitope, so they have monovalent affinity with identical offspring of a hybridoma or recombinant stable cell line. Monoclonal antibodies recognize and bind to antigens to distinguish specific epitopes that provide protection against the pathogens. It is possible for any substance to produce monoclonal antibodies that can specifically bind to the substance and be used to detect or purify the substance. It has become an important tool for the study of molecular biology, biochemistry and especially vaccines. Creative Biolabs provides protective monoclonal antibody discovery service for your vaccine development with fairly good sensitivity and specificity.

Monoclonal Antibody Vaccines

History

  • In the 1900s, first proposed by Paul Ehrlich: if a compound that selectively targeted a disease-causing organism could be made, then a toxin for that organism could be delivered along with the agent of selectivity.
  • In the 1970s, it was known that cancerous B-cells all produce a single type of antibody, which was not yet possible to produce identical antibodies specific to a given antigen.
  • In 1975, Georges Köhler and César Milstein succeeded in making fusions of myeloma cell lines with B cells to create hybridomas that could produce antibodies, specific to known antigens and that were immortalized.
  • In 1985, phage display was first described by George P. Smith. He demonstrated the display of peptides on filamentous phage by fusing the peptide of interest onto gene III of filamentous phage. This technology was further developed for display of proteins such as antibodies for therapeutic protein engineering.

Production of Monoclonal Antibodies

Based on our monoclonal antibody production technology, we offer contract services for custom monoclonal antibody production.

Hybridoma Technique

Monoclonal antibodies are typically produced by cell culture, which involves fusing the myeloma cells with mouse spleen cells immunized with the desired antigen. The selection medium is called HAT medium because it contains hypoxanthine, aminopterin, and thymidine. The medium is selective for fused (hybridoma) cells. Only fused hybrid cells can grow indefinitely in the culture medium. Hybridomas can grow indefinitely in the appropriate cell culture medium. They can also be injected into mice (in the peritoneal cavity, surrounding the gut).

A general representation of the method used to develop monoclonal antibodies via hybridoma technology

Fig. 2 A general representation of the method used to produce monoclonal antibodies

After obtaining the culture sample or ascitic fluid sample of the cultured hybridoma, the desired antibody must be extracted. Cell culture sample contaminants are mainly composed of culture medium components such as growth factors, transferrins, and hormones. While in vivo samples may have host antibodies, nucleases, nucleic acids, proteases, and viruses. There may also be bacterial contamination. The sample must be purified for application.

Microbial Display

Because the antibody paratope is well understood, as mentioned in the Introduction section, several approaches have been developed to produce synthetic combinatorial libraries for the identification of human mAbs for specific targets.

Phage display is the most widely used selection method. In this technique, the gene encoding the protein of interest is inserted into the phage coat protein gene so that it contains the gene for the protein on its inside while expressing the protein on its outside. These displaying phages can then be screened against other proteins, peptides or DNA sequences to detect the interaction between the displayed protein and those other molecules.

Monoclonal Antibodies in Vaccine Development

Monoclonal antibodies are commonly used protein molecules and have many applications in human health. There are more than 30 therapeutic monoclonal antibody drugs approved for marketing currently and about 360 mAbs in clinical studies, including cancer, autoimmune diseases, and infectious diseases. In preclinical studies, understanding the mechanism of mAb interaction with the target is critical for vaccine design.

In terms of the extensive experience in monoclonal antibody research, Creative Biolabs is proud to offer our customers a series of detection monoclonal antibodies as well as protective mAb vaccine design services with the best quality and most competitive price.


Our services are for research use only. We do not provide services directly to individuals.

Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Project Description:
*Verification Code:
Verification code
Click image to refresh the verification code.

CONTACT US

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:


Follow us on

facebook   twitter   linked   blog

Shopping Basket